← Leaderboards
Peter M Gordon
Boston Children'S Hospital
$3,165,051
Attributed
$3,369,300
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $641.4K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,369,300 · 4
By mechanism
R37$2,088,992 · 1
K08$716,810 · 1
R21$408,498 · 1
R03$155,000 · 1
Top collaborators
- Stuart Sheldon Winter2 shared
Most similar at Boston Children'S Hospital
Same institution · by research overlap
- Tobias Neff$730,080
- Daniel Evan Bauer$19,160,492
- Inga Hofmann Zhang$683,596
- Aniruddha J. Deshpande$4,851,829
Others in their field
Top investigators on “Relapse”
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Charles A Coltman · Southwest Oncology Group$124,514,512
- Mary M Horowitz · Medical College Of Wisconsin$85,160,686
- Monica M Bertagnolli · Strang Cancer Prevention Center$41,995,734
- Effie W Petersdorf · Fred Hutchinson Cancer Research Center$29,676,600
- Misty Ward Stevens · Intervexion Therapeutics, Llc$28,867,910
Research focus
RelapseMediatingMolecularPathway InteractionsCell SurvivalBiological ModelsLeukemiaLeukemic CellClinicRegulationNovel Therapeutic InterventionTranslatingApoptosisIn VivoCellsLinkIn VitroApoptoticAntibodiesInsightAcute Lymphocytic LeukemiaGeneticChemotherapyCell Communication
Grant awards (16)
Overcoming Leukemia Chemoresistance in the Central Nervous System$352,275
R37 · FY2025 · CA · contact PI
Overcoming Leukemia Chemoresistance in the Central Nervous System$334,662
R37 · FY2024 · CA · contact PI
A Novel VpreB1 Anti-body Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma$189,780
R21 · FY2024 · CA
Overcoming Leukemia Chemoresistance in the Central Nervous System$345,230
R37 · FY2023 · CA · contact PI
A Novel VpreB1 Anti-body Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma$218,718
R21 · FY2023 · CA
Development of a Novel Method for the Identification and Characterization of Intercellular Communication in the Cancer Niche$77,500
R03 · FY2023 · CA · contact PI
Overcoming Leukemia Chemoresistance in the Central Nervous System$352,275
R37 · FY2022 · CA · contact PI
Development of a Novel Method for the Identification and Characterization of Intercellular Communication in the Cancer Niche$77,500
R03 · FY2022 · CA · contact PI
Overcoming Leukemia Chemoresistance in the Central Nervous System$352,275
R37 · FY2021 · CA · contact PI
Overcoming Leukemia Chemoresistance in the Central Nervous System$352,275
R37 · FY2020 · CA · contact PI
Autophagy and Apoptosis in the Response of c-KIT Cancers to Targeted Therapy$143,362
K08 · FY2015 · CA · contact PI
Autophagy and Apoptosis in the Response of c-KIT Cancers to Targeted Therapy$143,362
K08 · FY2014 · CA · contact PI
Autophagy and Apoptosis in the Response of c-KIT Cancers to Targeted Therapy$71,911
K08 · FY2013 · CA · contact PI
Autophagy and apoptosis in the response of c-KIT cancers to targeted therapy$71,451
K08 · FY2013 · CA · contact PI
Autophagy and apoptosis in the response of c-KIT cancers to targeted therapy$143,362
K08 · FY2012 · CA · contact PI
Autophagy and apoptosis in the response of c-KIT cancers to targeted therapy$143,362
K08 · FY2011 · CA · contact PI